TB-500

Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.

The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.

Thymosin Beta-4 fragment — systemic tissue repair, cell migration, and full-body recovery peptide.

A 43-residue peptide (or its Ac-SDKP N-terminal tetrapeptide fragment) characterised as a G-actin-sequestering molecule with published effects on cytoskeletal dynamics and vascular remodelling in preclinical models. For laboratory characterisation only.

TB-500 (Thymosin Beta-4 Fragment) — clinical & mechanistic profile

TB-500 is a synthetic 7-amino-acid fragment from thymosin beta-4's actin-binding site. A Phase 1/2 trial launched February 2026 investigates its cardiovascular effects in adults with stable atherosclerotic disease. Phase 1 safety data in 84 healthy volunteers showed favorable tolerability. 2025 research reveals its wound-healing activity may stem from the metabolite Ac-LKKTE rather than the parent compound.

What TB-500 (Thymosin Beta-4 Fragment) is

TB-500 (Thymosin Beta-4 Fragment) is a synthetic heptapeptide fragment of thymosin beta-4. TB-500 is a synthetic 7-amino-acid fragment from thymosin beta-4's actin-binding site. A Phase 1/2 trial launched February 2026 investigates its cardiovascular effects in adults with stable atherosclerotic disease. Phase 1 safety data in 84 healthy volunteers showed favorable tolerability. 2025 research reveals its wound-healing activity may stem from the metabolite Ac-LKKTE rather than the parent compound. It has a molecular formula C212H350N56O78S (full Tβ4), mass 4963 Da (full Tβ4) / ~900 Da (TB-500 fragment) Da. Its published amino-acid sequence is Ac-LKKTETQ (active fragment of 43-aa Tβ4). Common synonyms in the literature include Thymosin Beta 4, Tβ4, and TB4.

Investigation of TB-500 (Thymosin Beta-4 Fragment) to date is clinical-investigational, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing TB-500 (Thymosin Beta-4 Fragment) spans Dermal wound healing models: Phase 2 human trials for stasis and pressure ulcers showed accelerated healing by almost a month in responding patients. Day 4 topical application showed 42% improvement in reepithelialization vs. saline controls, increasing to 61% by day 7. Animal studies demonstrated thicker collagen fiber bundles with reduced wound width and scarring, Cardiac injury research: Human clinical trials explored TB-4's ability to protect and repair cardiac tissue following acute myocardial infarction. In one trial, endothelial progenitor cells combined with TB-4 were transplanted into post-MI patients, showing improved walk time and cardiac function after 6 months. Animal studies indicate TB-4 helps repair heart damage and improves cardiac vasculature, and Musculoskeletal models: Rodent studies have examined TB-500 in muscle injury, tendon healing, and ligament repair contexts. Observations include effects on fibroblast activity, collagen organization, and biomechanical recovery metrics. Proposed mechanisms in the literature include G-actin sequestration: binds G-actin 1:1, inhibits F-actin polymerization, modulates actin structures in hypoxic cardiac cells and ROCK1/MRTFA pathway: decreases ROCK1 protein, reduces profibrotic signaling via MRTFA/SRF in cardiac cells under hypoxia. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for TB-500 (Thymosin Beta-4 Fragment) outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on TB-500 (Thymosin Beta-4 Fragment), see the TB-500 (Thymosin Beta-4 Fragment) research page. All references cited on that page are peer-reviewed primary literature.

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found in high concentrations in blood platelets, wound fluid, and other tissues. Thymosin Beta-4 was originally isolated from thymus extracts in the 1960s and has since been identified as a major actin-sequestering protein with significant roles in cell migration, differentiation, and cellular pathway. TB-500 represents a truncated, active region of the full Thymosin Beta-4 molecule, making it more practical for research applications while retaining the key biological activity associated with the parent molecule.

TB-500's biological effects stem from several well-characterized mechanisms that have been studied extensively in laboratory and preclinical settings:

Cardiac Research : TB-500/Thymosin Beta-4 has been extensively studied in cardiac research. Studies in animal models of myocardial infarction have shown reduced scar formation, improved cardiac function, and enhanced survival of cardiomyocytes. Clinical trials have explored its potential in cardiac cellular-pathway research following heart attack. Corneal Healing Studies : Significant research has focused on TB-500's effects on corneal healing. Studies demonstrate accelerated corneal wound closure, reduced inflammation, and improved outcomes in various corneal injury models. This research led to clinical development of Thymosin Beta-4-based eye drops. Dermal Cellular Research : Research has examined TB-500's effects on skin wounds, including burns, incisions, and chronic wounds. Studies report accelerated wound closure, enhanced epithelialization, improved collagen organization, and reduced scarring in various experimental models. Musculoskeletal Research : Preclinical studies have investigated TB-500's effects on muscle, tendon, and ligament injuries. Research shows potential benefits for muscle strain recovery, tendon healing, and joint health, with observations of reduced inflammation and accelerated cellular pathway.

1.Allow vial to reach room temperature before reconstitution 2.Use bacteriostatic water for multi-use applications 3.Add solvent gently down the inside wall of the vial 4.Allow to dissolve naturally or gently swirl—never shake 5.Typical reconstitution: 2mL per 5mg vial yields 2.5mg/mL concentration

[1] Goldstein AL, et al. Thymosin beta4: a multi-functional structural peptide. Expert Opin Biol Ther. 2012;12(suppl 1):S37-S51. [2] Sosne G, et al. Thymosin beta 4 promotes corneal wound-model research and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299. [3] Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472. [4] Hinkel R, et al. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann N Y Acad Sci. 2010;1194:105-111.

Binding and functional-assay data for TB-500, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.

Two peptides frequently studied together in tissue-regeneration research. Reference chemistry only — no comparative-effectiveness claim expressed or implied.